subscribeSubscribe
price-trendAsk Us
Agios cashes in on cancer drug again with $905M Royalty Pharma deal

Agios cashes in on cancer drug again with $905M Royalty Pharma deal
Delilah Alvarado BIOPHARMADIVE
28 May 2024
Share Share
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty

Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
GLOBENEWSWIRE
28 May 2024
Share Share
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib
PR NEWSWIRE
21 Feb 2024
Share Share
FDA and EMA Accept Vorasidenib Regulatory Submissions for diffuse glioma

FDA and EMA Accept Vorasidenib Regulatory Submissions for diffuse glioma
PR NEWSWIRE
20 Feb 2024
Share Share
Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib`s Potential

Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib`s Potential
PR NEWSWIRE
18 Nov 2023
Share Share
Vorasidenib Data at SNO Bolster Servier`s Neuro-Oncology Development Program

Vorasidenib Data at SNO Bolster Servier`s Neuro-Oncology Development Program
PR NEWSWIRE
10 Nov 2023
Share Share
Servier Presents Transformational Data from Phase 3 INDIGO Trial of Vorasidenib

Servier Presents Transformational Data from Phase 3 INDIGO Trial of Vorasidenib
PR NEWSWIRE
04 Jun 2023
Share Share
Servier’s $1.8B bet on Agios delivers phase 3 brain tumor win

Servier’s $1.8B bet on Agios delivers phase 3 brain tumor win
Nick Paul Taylor FIERCE BIOTECH
15 Mar 2023
Share Share
Servier`s PIII INDIGO Trial Investigating vorasidenib Meets Primary Endpoint

Servier`s PIII INDIGO Trial Investigating vorasidenib Meets Primary Endpoint
PR NEWSWIRE
14 Mar 2023
Share Share
Agios Presents Updated Data from the Ph 1 Dose-escalation Study of Vorasidenib

Agios Presents Updated Data from the Ph 1 Dose-escalation Study of Vorasidenib
PRESS RELEASE
29 May 2020
Share Share